Meeting on Arsenic: Health Effects, Mechanisms of Actions, and Research Issues, Hunt Valley, Maryland, 22-24 September 1997

Environmental Health Perspectives

Volumn 107, Issue 7, 1999, Pages 593-597

  Abernathy, Charles O ^a,h   Liu, Yung Pin ^b   Longfellow, David ^b   Aposhian, H Vasken ^c   Beck, Barbara ^d   Fowler, Bruce ^e   Goyer, Robert ⁱ   Menzer, Robert ^a   Rossman, Toby ^f   Thompson, Claudia ^g   Waalkes, Michael ^g  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d GRADIENT   (United States)

^e UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^h US EPA   (United States)

ⁱ East Tower ^*

Author keywords

Aresenite; Arsenate; Arsenic; Dimethylarsinic acid; Heart shock proteins; Heme oxygenase; Monomethylarsonic acid; S adenosylmethionine

Indexed keywords

ARSENIC; DRINKING WATER; RADICAL; DNA;

BIOACCUMULATION; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DNA METHYLATION; DNA REPAIR; ENVIRONMENTAL EXPOSURE; ENZYME INHIBITION; GENE ACTIVATION; HEALTH; HEALTH HAZARD; INTESTINE CANCER; METABOLISM; METHODOLOGY; ONCOGENE C MYC; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SKIN CANCER; SYMPOSIUM; UNITED STATES; ARTICLE; CHEMICALLY INDUCED DISORDER; DNA DAMAGE; DOSE RESPONSE; DRUG EFFECT; HUMAN; NEOPLASM;

ANIMALIA;

ARSENIC; DNA; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS;

EID: 0033163427     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.99107593     Document Type: Conference Paper

References (30)

1. Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J Natl Cancer Inst 40:453-462 (1968).
2. Luo ZD, Zhang YM, Ma L, Zhang GY, He X, Wilson R, Byrd DM, Griffiths JG, Lai S, He L, et al. Chronic arsenicism and cancer in Inner Mongolia - consequences of well-water arsenic levels greater than 50 μg/I. In: Arsenic Exposure and Health Effects (Abernathy CO, Calderon RL, Chappell WR, eds). London:Chapman and Hall, 1997;55-68.
3. Aposhian HV. Enzymatic methylation of arsenic species and other approaches to arsenic toxicity. Annu Rev Pharmacol Toxicol 37:397-419 (1997).
4. Thompson DJ. A chemical hypothesis for arsenic methylation in mammals. Chem Biol Interact 88:89-114 (1993).
5. Rossman TG. Molecular and genetic toxicology of arsenic. In: Environmental Toxicology: Current Developments (Rose J, ed). Amsterdam:Gordon and Breach Publishers, 1998;171-187.
6. Aoki Y, Lipsky MM, Fowler BA. Alteration of protein synthesis in primary cultures of rat kidney epithelial cells by exposure to gallium, indium and arsenic. Toxicol Appl Pharmacol 106:462-468 (1990).
7. Keyse SM, Tyrell RM. Heme oxygenase is the major 32-Kda stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl Acad Sci USA 86:99-103 (1989).
8. Healy SM, Casarez EA, Ayala-Fierro F, Aposhian HV. Enzymatic methylation of arsenic compounds. V: Arsenite methyltransferase activity in tissues of mice. Toxicol Appl Pharmacol 148:65-70 (1998).
9. Aposhian HV, Arroyo A, Cebrian ME, Del Razo LM, Hurlbut KM, Dart RC, Gonzalez-Ramirez D, Kreppel H, Spersky H, Smith A, et al. DMPS-arsenic challenge test. 1: Increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sulfonate. J Pharmacol Exp Ther 282:192-200 (1997).
10. Vahter M. Species differences in the metabolism of arsenic. In: Arsenic Exposure and Health (Chappell WR, Abernathy CO, Cothern CR, eds). Northwood, UK:Science and Technology Letters, 1994;171-179.
11. Vahter M, Concha G, Nermell B, Dulout F, Natarajan AT. A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol 293:455-462 (1995).
12. Mann S, Droz PO, Vahter M. A physiologically based pharmacokinetic model for arsenic exposure. II: Validation and applications in humans. Toxicol Appl Pharmacol 140:471-486 (1996).
13. Ferreccio C, Gonzalez Psych C, Milosavjlevic Stat V, Marshall Gredis G, Sancha AM. Lung cancer and arsenic exposure in drinking water: a case-control study in northern Chile. Cad Saude Publica 14:193-198 (1998).
14. Chen CJ. Personal communication.
15. Hseuh YM, Wu WL, Huang YL, Chiou HY, Chiou CH, Chen CJ. Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis 141:249-257 (1998).
16. Mandal BK, Chowdhury TR, Samanta G, Basu GK, Chowdhury PP, Chandra CR, Lodh D, Karan NK, Dhar RK, Tamili DK, et al. Arsenic in groundwater in seven districts of West Bengal, India - the biggest arsenic calamity in the world. Curr Sci 70:976-986 (1996).
17. Mazumder DN, Haque R, Ghosh N, De BK, Santra A, Chakraborty D, Smith A. Arsenic levels in drinking water and the prevalence of skin lesions in West Bengal, India. Int J Epidemiol 27:871-877 (1998).
18. Siripitayakunkit U, Visudhiphan P, Pradipasen M, Vorapongsathon T. Association between chronic arsenic exposure and children's intelligence in Thailand. Presented at the Third SEGH International Conference on Arsenic Exposure and Human Health, 12-15 July 1998, San Diego, California.
19. Lewis DR, Southwick JW, Oullet-Hellstrom R, Rench J, Calderon RL. Drinking water arsenic in Utah: a cohort mortality study. Environ Health Perspect 107:359-365 (1999).
20. National Research Council. Recommended Dietary Allowances, 10th ed. Washington, DC:National Academy Press, 1989
21. Uthus EO. Evidence for arsenic essentiality. Environ Geochem Health 14:55-58 (1992).
22. Nielson F. Other trace elements. In: Present Knowledge in Nutrition, 7th ed (Ziegler EE, Filer LJ, eds). Washington, DC:ILSI Press, 1995;353-377.
23. Zhao CQ, Young MR, Biwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 94:10907-10912 (1997).
24. Mass MJ, Wang L. Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutat Res 386:263-277 (1997).
25. Yamanaka K, Hayashi H, Kato K, Hasegawa A, Okada S. Involvement of preferential formation of apurinic/apyrimidinic sites in dimethylarsenic-induced DNA strand breaks and DNA-protein cross-links in cultured alveolar epithelial cells. Biochem Biophys Res Commun 207:244-249 (1995).
26. Eastern Research Group. Report on the Expert Panel on Arsenic Carcinogenicity: Review and Workshop. EPA contract no. 68-C6-0041. Lexington, MA:Eastern Research Group for the National Center for Environmental Assessment, 1997.
27. Nriagu JO, ed. Arsenic in the Environment. Part I: Cycling and Characterization. New York:John Wiley & Sons, Inc., 1994.
28. Nriagu JO, ed. Arsenic in the Environment. Part II: Human Health and Ecosystems Effects. New York:John Wiley & Sons, Inc., 1994.
29. Chappell WR, Abernathy CO, Cothern CR, eds. Arsenic Exposure and Health. Northwood, UK:Science and Technology Letters, 1994.
30. Abernathy CO, Calderon RL, Chappell WR, eds. Arsenic Exposure and Health Effects. London: Chapman and Hall, 1997.